

BioDrugs

## **The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland**

### **Authors:**

Saana V. Luukkanen

Clinical Pharmacy Group, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy,  
University of Helsinki, Helsinki, Finland

OrcidID: <https://orcid.org/0000-0002-2329-166X>

Hanna M. Tolonen

HUS Pharmacy, HUS Helsinki University Hospital, Helsinki, Finland

Clinical Pharmacy Group, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy,  
University of Helsinki, Helsinki, Finland

OrcidID: <https://orcid.org/0000-0002-6824-7566>

Marja Airaksinen

Clinical Pharmacy Group, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy,  
University of Helsinki, Helsinki, Finland

OrcidID: <https://orcid.org/0000-0002-6077-5671>

Laura S. M. Saarukka

Clinical Pharmacy Group, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy,  
University of Helsinki, Helsinki, Finland

OrcidID: <https://orcid.org/0000-0001-8153-3033>


### **Correspondence to:**

Saana Luukkanen


[saana.luukkanen@helsinki.fi](mailto:saana.luukkanen@helsinki.fi)

**The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland**

Luukkanen SV, Tolonen HM, Airaksinen M, Saarukka LSM




**Online Resource Fig. 1** The development of the market shares and weighted average prices of the somatropin reference product (R) and its biosimilar (B) starting January 1, 2009, and ending August 31, 2020.




**Online Resource Fig. 2** The development of the market shares and weighted average prices of the epoetin reference product (R) and its biosimilars (B1, B2) starting January 1, 2009, and ending August 31, 2020. The number in the biosimilar’s abbreviation refers to the order of the biosimilars entering the market.

**The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland**

Luukkanen SV, Tolonen HM, Airaksinen M, Saarukka LSM




**Online Resource Fig. 3.** The development of the market shares and weighted average prices of the filgrastim reference product (R) and its biosimilars (B1, B2, B3, B4) starting January 1, 2009, and ending August 31, 2020. The gray dashed line represents the moment when the first filgrastim biosimilar entered the market. The wholesale weighted average price of the first filgrastim biosimilar was observed from January 2010 when its regular sales began. The number in the biosimilar’s abbreviation refers to the order of the biosimilars entering the market.




**Online Resource Fig. 4.** The development of the market shares and weighted average prices of the follitropin reference product (R) and its biosimilars (B1, B2) starting three years before the first biosimilar entered the market and ending August 31, 2020. The gray dashed line represents the moment when the first follitropin biosimilar entered the market. The wholesale weighted average price of the first follitropin biosimilar was observed from December 2014 when its sales began. The number in the biosimilar’s abbreviation refers to the order of the biosimilars entering the market.

**The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland**

Luukkanen SV, Tolonen HM, Airaksinen M, Saarukka LSM




**Online Resource Fig. 5.** The development of the market shares and weighted average prices of the insulin glargine reference product (R) and its biosimilar (B), and other insulin product (O), starting three years before the biosimilar entered the market and ending August 31, 2020. The gray dashed line represents the moment when the insulin glargine biosimilar entered the market.




**Online Resource Fig. 6.** The development of the market shares and weighted average prices of the insulin lispro reference product (R) and its biosimilar (B), and other insulin product (O), starting three years before the biosimilar entered the market and ending August 31, 2020. The gray dashed line represents the moment when the insulin lispro biosimilar entered the market.

**The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland**

Luukkanen SV, Tolonen HM, Airaksinen M, Saarukka LSM




**Online Resource Fig. 7.** The development of the market shares and weighted average prices of the etanercept reference product (R) and its biosimilar (B) starting three years before the biosimilar entered the market and ending August 31, 2020. The gray dashed line represents the moment when the etanercept biosimilar entered the market.




**Online Resource Fig. 8.** The development of the market shares and weighted average prices of the pegfilgrastim reference product (R) and its biosimilars (B1, B3) starting three years before the first biosimilar entered the market and ending August 31, 2020. The gray dashed line represents the moment when the first pegfilgrastim biosimilar entered the market. The wholesale weighted average price of the first pegfilgrastim biosimilar was observed from December 2018 when its sales began. The number in the biosimilar’s abbreviation refers to the order of the biosimilars entering the market. The second and fourth biosimilars were not sold over the observation period.

**The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland**

Luukkanen SV, Tolonen HM, Airaksinen M, Saarukka LSM




**Online Resource Fig. 9.** The development of the market shares and weighted average prices of the adalimumab reference product (R) and its biosimilars (B1, B2, B3, B4) starting three years before the first biosimilar entered the market and ending August 31, 2020. The gray dashed line represents the moment when the first adalimumab biosimilar entered the market. The number in the biosimilar’s abbreviation refers to the order of the biosimilars entering the market.



**Online Resource Fig. 10.** The development of the market shares and weighted average prices of the teriparatide reference product (R) and its biosimilar (B) starting three years before the biosimilar entered the market and ending August 31, 2020. The gray dashed line represents the moment when the teriparatide biosimilar entered the market. The wholesale weighted average price of the first teriparatide biosimilar was observed from May 2020 when its sales began.

**The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland**

Luukkanen SV, Tolonen HM, Airaksinen M, Saarukka LSM



**Online Resource Fig. 11.** The development of the market shares and weighted average prices of the enoxaparin reference product (R) and its biosimilars (B1, B2, B3) starting three years before the first biosimilar entered the market and ending August 31, 2020. The gray dashed line represents the moment when the first enoxaparin biosimilar entered the market. The number in the biosimilar’s abbreviation refers to the order of the biosimilars entering the market.